Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies
Panelists discuss how the evaluation and treatment initiation processes for non-BCMA targeted bispecifics and BCMA-targeted bispecifics share core similarities in patient assessment and care coordination, but differ in specific premedication protocols, dosing strategies, and side effect management.
EP: 1.The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration
EP: 2.Fast-Tracking Care: Streamlining Referrals for Quicker Treatment in Multiple Myeloma
EP: 3.Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?
EP: 4.Overcoming Challenges in Patient Referrals: Handling Reluctance and Navigating Barriers to Academic Care
EP: 5.When Is the Right Time? Navigating Key Moments for Referring Multiple Myeloma Patients to an Academic Center
EP: 6.Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care
EP: 7.Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care
EP: 8.Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled
EP: 9.Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies
EP: 10.Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
EP: 11.Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma
EP: 12.Protocols for Monitoring and Managing Long-Term Complications of Bispecific Therapy in Mutlplie Myeloma
EP: 13.Enhancing Communication Between Academic and Community Oncologists During Referral and Treatment in Multiple Myeloma.
EP: 14.Optimizing Patient Reintegration into Community Care Post-Academic Treatment of Bispecifics in Multiple Myeloma
EP: 15.Unmet Needs and Future Directions for Enhancing Bispecific Therapy Care Transitions in Multiple Myeloma
Video content above is prompted by the following:
- Is the process different/similar for patients who might be receiving non-BCMA targeted bispecific vs BCMA-bispecific?
- Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step up dosing, premedication/prophylaxis, etc.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
